TYMP thymidine phosphorylase
ENSG00000025708 · protein coding · Open Targets profile
May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro. .
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, High-Quality Pocket, Druggable Family
- PROTAC
- Half-life Data, Small Molecule Binder
gnomAD loss of function constraint: o/e 1.0887000560760498 (upper bound 1.3919999599456787). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 154 registry trials, updated in the last three years, of the most advanced drugs against TYMP (tipiracil), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Fortunato CiardielloA.O.U. dell'Università degli studi della Campania "Luigi Vanvitelli" · 3 of 3 trials Phase 2+Ph2NCT05312398 · CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimenbrief
- Jing HaoQilu Hospital of Shandong University · 2 of 2 trials Phase 2+
- John H StricklerAcademic and Community Cancer Research United · 2 of 2 trials Phase 2+
- Salah-Eddin Al-BatranInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · 2 of 2 trials Phase 2+
- Ying YuanSecond Affiliated Hospital, Zhejiang University, School of Medicine · 2 of 2 trials Phase 2+
- Yongkun SunCancer Institute and Hospital, Chinese Academy of Medical Sciences · 2 of 2 trials Phase 2+
- Christos FountzilasRoswell Park Cancer Institute · 1 of 2 trials Phase 2+
- Scott KopetzM.D. Anderson Cancer Center · 1 of 2 trials Phase 2+
- A. Elise van Leeuwen-StokBOOG Study Center · 1 of 1 trials Phase 2+
- Abdullah EsmailHouston Methodist Neal Cancer Center · 1 of 1 trials Phase 2+
- Aiping ZhouCancer Institute and Hospital, Chinese Academy of Medical Sciences · 1 of 1 trials Phase 2+
- Alessandro PassardiIRCCS IRST · 1 of 1 trials Phase 2+
- Alexander SteinHämatologisch-Onkologische Praxis Eppendorf University Cancer Center Hamburg · 1 of 1 trials Phase 2+
- Alisha BentM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
- Benjamin OshrineParabilis Medicines, Inc. · 1 of 1 trials Phase 2+
Registry trials of tipiracil updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 111 of 147 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 7 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
23 trials of drugs against TYMP were stopped early; 1 give no reason
Terminated, withdrawn and suspended interventional trials of tipiracil, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 23 most recent of 23.
- suspended · 2026-11-02 · M.D. Anderson Cancer Center · Trifluridine + Tipiracil“PI Request”
- suspended · 2026-10-20 · Case Comprehensive Cancer Center · Trifluridine/tipiracil“Interim Analysis”
- withdrawn · 2026-10-05 · Biotech Pharmaceutical Co., Ltd. · Trifluridine/tipiracil“Study withdrawn before enrollment of any participant due to a corporate strategic decision. Not related to safety or efficacy concerns.”
- suspended · 2026-09-18 · Holy Stone Healthcare Co., Ltd · matched by the registry's drug synonyms“Strategy under discussion”
- terminated · 2026-08-26 · Bristol-Myers Squibb · matched by the registry's drug synonymsNo reason given
- terminated · 2026-08-14 · Astellas Pharma Global Development, Inc. · Trifluridine + Tipiracil“Lack of clinical benefit”
- suspended · 2026-02-03 · Gruppo Oncologico del Nord-Ovest · Trifluridine/Tipiracil“due to earlier termination of the agreement between the Sponsor and Central Laboratory for screening test. Enrollment will reopen as soon as a new laboratory is identified.”
- terminated · 2025-11-04 · Baylor Research Institute · matched by the registry's drug synonyms“Study halted due to low enrollment”
- terminated · 2025-03-30 · UNICANCER · Regorafenib then Trifluridine/Tipiracil, Trifluridine/Tipiracil then Regorafenib“Following the presentation of the SUNLIGHT study results at ASCO GI and the rapid change in patient management in the majority of centers, the IDMC experts recommended halting inclusion in the SOREGATT study with immediate effect.”
- withdrawn · 2024-09-19 · Academic and Community Cancer Research United · Trifluridine and Tipiracil Hydrochloride“no sites were regulatory ready and the SC took the study to a different group.”
- terminated · 2024-09-05 · Taiho Oncology, Inc. · matched by the registry's drug synonyms“The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed an imbalance of PFS between the two arms”
- terminated · 2024-08-20 · Institut de Recherches Internationales Servier · Trifluridine/Tipiracil“Sponsor decided to discontinue the study during the Lead-In part and the Phase III part was not started due to strategic reasons.”
- terminated · 2024-05-02 · Elevar Therapeutics · Trifluridine/Tipiracil“Phase 2 portion of the study was not performed due to redirection of the rivoceranib development plan by the Sponsor.”
- terminated · 2024-01-05 · Patrick Joseph Loehrer Sr. · matched by the registry's drug synonyms“Unable to proceed due to Neulasta difficulties and other complications.”
- terminated · 2023-11-03 · Karyopharm Therapeutics Inc · Tipiracil“Sponsor decision”
- terminated · 2023-09-18 · GERCOR - Multidisciplinary Oncology Cooperative Group · Trifluridine/Tipiracil“Recruitment failure”
- terminated · 2023-02-22 · Universitätsklinikum Hamburg-Eppendorf · Trifluridine/tipiracil chemoradiation“Due to the amended therapy strategies for rectal cancer recently, it was decided not to transfer the study to the phase II part, as superiority over standard chemoradiation and transfer to a new therapy standard are increasingly unlikely.”
- terminated · 2022-12-01 · Sunnybrook Health Sciences Centre · Trifluridine/Tipiracil“Lack of Funding”
- terminated · 2022-09-23 · University of Wisconsin, Madison · matched by the registry's drug synonyms“closed per sponsor request, for slow enrollment”
- terminated · 2021-02-04 · University of Florida · matched by the registry's drug synonyms“insufficient time to accrue sufficient subjects before end of funding”
- withdrawn · 2020-06-11 · AHS Cancer Control Alberta · Trifluridine/Tipiracil“Sponsor withdrew support”
- withdrawn · 2019-02-04 · Symphogen A/S · matched by the registry's drug synonyms“Study was withdrawn due to administrative reasons”
- terminated · 2018-08-07 · Georgetown University · matched by the registry's drug synonyms“Principal investigator left the institution”
Paediatric incentives and obligations for TYMP's drugs
For tipiracil: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · TYMP is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: no · No EMA paediatric investigation plan decision names tipiracilRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: no · No EU orphan designation names tipiracilRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Lonsurf: authorised since 25 Apr 2016Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Lonsurf, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of tipiracilRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 3 interventional studies of tipiracil include patients under 18; 2 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 2 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.